Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002382557 | SCV002672062 | uncertain significance | Cardiovascular phenotype | 2019-12-17 | criteria provided, single submitter | clinical testing | The c.72670+2T>C intronic variant results from a T to C substitution two nucleotides after coding exon 182 in the TTN gene. Coding exon 182 is located in the A-band region of the N2-B isoform of the titin protein and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This variant (referred to as c.94942+2T>C) has been detected in an individual from a control cohort not known to have cardiomyopathy (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28). This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing and often result in a transcript encoding a truncated protein. However, one of the predicted consequences of this alteration would be skipping of coding exon 182, leading to an in-frame deletion that may not result in protein truncation. Truncating variants in the A-band of titin are the most common cause of dilated cardiomyopathy (DCM), and, regardless of their position, truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM (Herman DS et al. N. Engl. J. Med. 2012;366:619-28; Roberts AM et al. Sci Transl Med. 2015;7:270ra6; Schafer S et al. Nat. Genet. 2017;49:46-53). However, TTN truncating variants have also been reported in 1-3% of the general population (Herman DS et al. N. Engl. J. Med. 2012;366:619-28). Since the exact splicing impact of this alteration is unknown and supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Institute of Immunology and Genetics Kaiserslautern | RCV004546720 | SCV005043034 | uncertain significance | Hypertrophic cardiomyopathy 9 | 2024-04-25 | criteria provided, single submitter | clinical testing | ACMG Criteria: PM2, PP3, PVS1_M; Variant was found in heterozygous state |